You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

218 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Updated
Oct 2025

Pages